Investment Landscape: Alzheimer's Disease covers the current R&D investment, [@clinicaltrialsgov] clinical trial pipeline, and funding trends for Alzheimer's Disease research.
Last updated: 2026-03-17 19:20 PT
Clinical Trial Pipeline
Total Clinical Trials: 4910
Active Trials (Recruiting/Active): 1208
Alzheimer's disease represents the largest neurodegenerative investment area with 4,910 total clinical trials. The pipeline shows 480 Phase 1, 636 Phase 2, and 321 Phase 3 trials currently active. The high number of completed trials (2529) reflects decades of research investment, though the limited Phase 3 count indicates significant attrition in later-stage development.
Key Investment Themes
...
Investment Landscape: Alzheimer's Disease
Overview
Investment Landscape: Alzheimer's Disease covers the current R&D investment, [@clinicaltrialsgov] clinical trial pipeline, and funding trends for Alzheimer's Disease research.
Last updated: 2026-03-17 19:20 PT
Clinical Trial Pipeline
Total Clinical Trials: 4910
Active Trials (Recruiting/Active): 1208
Alzheimer's disease represents the largest neurodegenerative investment area with 4,910 total clinical trials. The pipeline shows 480 Phase 1, 636 Phase 2, and 321 Phase 3 trials currently active. The high number of completed trials (2529) reflects decades of research investment, though the limited Phase 3 count indicates significant attrition in later-stage development.
Key Investment Themes
Disease Modification: Majority of trials focus on disease-modifying therapies targeting [amyloid-beta](/proteins/amyloid-beta) and tau pathology
Early Intervention: Growing emphasis on preclinical and prodromal AD trials
Biomarker Development: Increased investment in diagnostic and prognostic biomarkers
Combination Therapies: Rising interest in multi-target approaches
Emerging Investment Areas
With 324 terminated trials historically, the field is actively exploring new modalities. [Microbiome](/entities/microbiome)-based approaches represent an emerging area with growing trial activity. Senolytic therapies targeting cellular senescence are entering early-phase trials. Gene therapy vectors for [APP](/entities/app-protein) and related genes are under development, though clinical translation remains challenging.
Priority Research Gaps
Late-Stage Development Bottleneck
Only 6.5% of trials are in Phase 3, indicating a significant gap between early discovery and late-stage clinical development. Investment in clinical trial infrastructure and regulatory engagement could accelerate late-stage programs.
Recommended Priorities
Phase 2→3 Translation: Enhance predictive biomarkers and clinical endpoints
Trial Design Innovation: Adaptive trials and platform protocols
Patient Recruitment: Investment in trial-ready cohorts and registry infrastructure
Therapeutic Target Priorities
Based on trial count analysis, the following mechanism categories represent either well-invested areas or underserved opportunities:
amyloid: 395 trials - Well-established
mitochondrial: 346 trials - Well-established
genetic: 226 trials - Well-established
tau: 118 trials - Well-established
tauro: 118 trials - Well-established
Recent Investment Developments (2024-2025)
Approved Therapies
The Alzheimer's investment landscape has been transformed by the 2023-2024 approvals of disease-modifying therapies:
[Lecanemab](/entities/lecanemab) (Leqembi, Biogen/Eisai): Full FDA approval in July 2023, CMS coverage decision expanded in 2024
[Donanemab](/entities/donanemab) (Kisunla, Eli Lilly): FDA approved July 2024, first amyloid-targeting therapy with potential for limited treatment duration
Other candidates: Gantenerumab (Roche) discontinued in 2022; Crenezumab (Roche) showed limited efficacy
Key Pipeline Updates (2025)
RNL-441 (Lundbeck): Anti-amyloid antibody in Phase 3 for early AD
AL-002 (Alector/GSK): TREM2 agonist advancing in Phase 2
ACI-35 (ACI): Lipid-based tau vaccine in Phase 2
Semorinemab (Roche): Anti-tau antibody showing promise in Phase 2
Protollin (Prothelia): Novel immunotherapy with Phase 2 data expected 2025
Investment Themes
Combination approaches: Amyloid removal + tau targeting + neuroinflammation modulation
Early intervention: Trials in pre-symptomatic populations with biomarker confirmation
Generic/biosimilar competition: Expected for approved antibodies by 2028-2030
Investment Outlook
Near-Term Opportunities (1-3 Years)
Continued Phase 2/3 readouts expected for leading mechanisms. Focus on biomarker-positive trials for enrichment. Regulatory pathways becoming clearer for disease-modifying therapies.
Medium-Term Opportunities (3-5 Years)
Gene therapies and RNA-targeting modalities expected to expand. Combination therapy trials likely to increase. Patient stratification through genetic and biomarker testing becoming standard.
Long-Term Vision (5-10 Years)
Prevention trials in pre-symptomatic populations. Personalized medicine approaches based on genetic profiles. Disease-modifying therapies potentially becoming standard of care.